Previous Close | 48.00 |
Open | 48.00 |
Bid | 39.00 |
Ask | 44.00 |
Strike | 60.00 |
Expire Date | 2026-01-16 |
Day's Range | 48.00 - 48.00 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Q1 2024 Legend Biotech Corp Earnings Call
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.